HALT-C Existing Ancillary Studies

There are currently 20 ancillary studies being conducted in conjunction with the HALT-C Trial. Click on the links for more information about each study.

Immunologic and Virologic Correlates of Liver Fibrosis
Hepatic Steatosis in Chronic Hepatitis C: Risk Factors and Role in the Development of Hepatic Fibrosis
Serum Fibrosis Markers in Chronic Hepatitis C
Cognitive Effects of Long-Term Pegylated Interferon in Patients with Chronic Hepatitis C
Pre-Study Serial Histology as a Predictor of Response to Continuous Therapy During the HALT-C Trial
Quantitative Assessment of Hepatic Function in Chronic Hepatitis C
Risk Factors for Progression of Liver Disease in Chronic Hepatitis C
Iron and HFE Mutations in Chronic Hepatitis C
Bayer Versant bDNA 3.0 Quantification and TMA Detection of HCV RNA for the HALT-C Trial
Measurement of Serum Des-γ-Carboxy Prothrombin (DCP) for Early Detection of Hepatocellular Carcinoma (HCC) in Patients with Chronic Hepatitis C Virus (HCV) Infection
Clinical Utilities of AFP-L3 Determination in Early Recognition, Diagnosis and Prognosis of Hepatocellular Carcinoma in Patients with Chronic Hepatitis C
Influence of Host Genes on the Course of Chronic Hepatitis C
Analysis of Gene Expression in HCV-Infected Liver: Identification of Genes Associated with Responsiveness to Pegylated Interferon and Ribavirin therapy
Genetic Predictors of Depressive Symptoms Among Patients Treated With Interferon-α
Genetic Polymorphisms Associated with Non-Response to Treatment of Chronic HCV Infection
Effects of Interferon on Portal Hypertension Ancillary Study
HCV RNA Testing in HALT-C Sustained Virologic Responders
The Impact of Peginterferon Alfa-2a Maintenance Therapy On Portal Hypertension in Patients With Chronic Hepatitis C Virus Infection and Advanced Fibrosis and Cirrhosis Enrolled in the HALT-C Trial
Quasispecies Analysis of HCV Breakthroughs Occurring During the HALT-C Trial Lead-In Treatment Phase
Role of HCV sequence variation in liver pathology